UBS Maintains Neutral on Medpace Holdings, Raises Price Target to $700

Benzinga · 1d ago
UBS analyst Kevin Caliendo maintains Medpace Holdings (NASDAQ:MEDP) with a Neutral and raises the price target from $673 to $700.